Two cancer drugs already sitting in U.S. pharmacies reversed Alzheimer’s brain damage in mice

Researchers screening thousands of already-approved medications for an unexpected second use report that two cancer drugs reversed markers of Alzheimer’s-like brain damage in mice. The compounds, letrozole and irinotecan, are already stocked in pharmacies across the country for breast cancer and colorectal cancer respectively, which means any effort to test them in Alzheimer’s patients could skip years of the toxicology and dosing work normally required before a brand-new drug ever reaches a clinical trial.

How letrozole and irinotecan ended up on the list

The pair emerged from a computational approach that compares the gene-activity fingerprint of a disease against the gene-activity fingerprints produced by thousands of existing drugs, searching for medications that push cellular activity in the opposite direction from what the disease causes. Applied to tissue samples carrying the hallmark gene-expression changes of Alzheimer’s disease, the analysis flagged letrozole and irinotecan as two of the compounds most likely to reverse those patterns, despite neither drug having any prior, established connection to neurology or dementia care. Researchers have used similar computational screens to search for repurposing candidates in other neurodegenerative diseases, including Parkinson’s disease, on the theory that a disease’s gene-expression signature can point toward existing drugs no one had previously considered.

What changed in the mouse brains

When the two drugs were given together to mice engineered to develop Alzheimer’s-like pathology, the animals showed fewer of the cellular hallmarks associated with the disease, including reduced DNA damage in brain cells and a drop in markers tied to neuron loss. The treated mice also performed better on maze-based memory tests than untreated animals with the same genetic predisposition, suggesting the cellular-level changes translated into a measurable behavioral difference rather than remaining a lab curiosity. Researchers reported the improvements after a defined treatment period rather than a single dose, indicating the effect built up with repeated exposure similar to how the drugs are already dosed in cancer care.

Why an approved cancer drug can move faster than a new compound

Drug repurposing appeals to researchers precisely because it shortens the road to a clinical trial. Both letrozole and irinotecan already carry decades of human safety data, established dosing guidelines, and documented side-effect profiles from oncology use, all of which a newly discovered compound would have to generate from scratch through animal studies and early-phase human trials. That existing paper trail is why a repurposed drug can, in some cases, reach a small human trial years faster than a molecule designed specifically to target Alzheimer’s disease, and at a fraction of the cost typically associated with developing an entirely new compound from early discovery through approval.

Two very different drugs, one shared effect

Letrozole is an aromatase inhibitor that lowers estrogen production and is prescribed mainly to postmenopausal women with hormone-sensitive breast cancer, while irinotecan is a chemotherapy agent that blocks an enzyme cancer cells need to copy their DNA and is used chiefly against colorectal cancer. Their mechanisms have little obvious overlap, according to the NBC News report on the findings, which is part of why the combined effect on Alzheimer’s-related brain changes caught the research team’s attention. The result points toward Alzheimer’s disease involving multiple biological pathways that different drug classes can each partially address, rather than a single mechanism a single drug could fix on its own, and it has prompted researchers to ask whether other hormone-modulating or DNA-repair-related drugs might show similar effects if tested.

The gap between a mouse study and a treatment

Mice engineered to mimic Alzheimer’s disease do not fully replicate the human condition, and a chemotherapy drug’s side effects, including its impact on blood cell counts and the digestive system, are far more tolerable in a cancer patient facing a life-threatening illness than they would be in an otherwise healthy older adult being treated only for memory loss. ScienceAlert‘s coverage of the study likewise notes that turning a mouse finding into a usable Alzheimer’s treatment would require new trials to establish whether a dose low enough to avoid chemotherapy-level side effects could still deliver a benefit in people. Earlier repurposing candidates for Alzheimer’s disease, including several diabetes drugs tested in prior trials, have shown promise in animal models only to produce mixed or inconclusive results once tested in larger human studies, a pattern researchers say tempers expectations for any single early finding.

Where this fits in the broader hunt for Alzheimer’s therapies

The finding lands in a field where most experimental Alzheimer’s drugs fail to reach approval, and the handful of treatments cleared in recent years target amyloid plaques rather than the broader cellular damage this mouse study focused on. Repurposing screens like the one that flagged letrozole and irinotecan have also identified diabetes and cardiovascular drugs as possible Alzheimer’s candidates in separate research, reflecting a wider shift toward mining the existing pharmacy for treatments rather than waiting years for drugs built from scratch. Whether either cancer drug advances to human testing depends on funding and regulatory decisions that have not yet been made, and researchers involved in the work have cautioned that any prescribing of letrozole or irinotecan for Alzheimer’s disease outside of a formal clinical trial would be premature given how early the finding remains.

This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.

More from Morning Overview